CMPS

COMPASS Pathways Plc - 10-Q Summary (Q2 2026)

Business Context and Reporting Period

Company: COMPASS Pathways Plc (CMPS)
Reporting Period: Quarter ended June 30, 2026
Business Overview: A clinical-stage biotechnology company developing COMP360, a psilocybin-based treatment for Treatment-Resistant Depression (TRD) and Post-Traumatic Stress Disorder (PTSD). The company has no approved products and has not generated product revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss for the three months ended June 30, 2026, increased significantly to $253.8 million from $38.4 million in the prior year period. This was primarily driven by a non-cash fair value change in warrant liabilities of $205.6 million.
• Warrant Liability Volatility: The fair value change of warrant liabilities swung from a gain of $16.9 million in the six months ended June 2025 to a loss of $74.7 million in the six months ended June 2026, largely due to the issuance of pre-funded warrants in the February 2026 Offering and stock price appreciation.
• Operating Expenses: Total operating expenses increased slightly year-over-year for the six-month period ($95.3M vs $92.5M). General and Administrative (G&A) expenses rose by $8.3 million, attributed to increased personnel and consulting fees for commercial preparedness. Research and Development (R&D) expenses decreased by $5.6 million due to lower clinical trial costs as Phase 3 programs near completion.
• Liquidity Position: Cash and cash equivalents increased from $149.6 million at year-end 2025 to $433.3 million at June 30, 2026, bolstered by $370.0 million in net financing proceeds.

Guidance, Outlook, and Management Commentary

• Clinical Progress: The company achieved primary endpoints in both Phase 3 pivotal trials (COMP005 and COMP006) for TRD. The FDA granted a rolling review of the New Drug Application (NDA) and issued a National Priority Voucher in April 2026. A Phase 2b/3 trial for PTSD (COMP202) was initiated in January 2026.
• Capital Resources: Management believes cash on hand ($433.3 million) is sufficient to fund operations and capital expenditures into 2028. This estimate assumes no major unforeseen changes in clinical timelines or commercialization costs.
• Financing Activity: Significant capital was raised in the first half of 2026, including a February 2026 Offering ($140.5M net proceeds), exercise of 2025 ADS warrants ($203.2M net proceeds), and a $50.0 million term loan tranche from Hercules Capital.
• Risks and Contingencies:
  • Regulatory Scheduling: Commercialization depends on the DEA rescheduling psilocybin from Schedule I to a lower schedule (II-V) following FDA approval.
  • Debt Covenants: The Hercules Loan Agreement includes a minimum cash covenant effective October 1, 2027, requiring cash to be at least 55% of the outstanding debt balance, unless market capitalization exceeds $850 million.
  • Tax Uncertainty: The company is in discussions with HMRC regarding eligibility for enhanced UK R&D tax credits, which could result in additional credits of up to $7.3 million for 2025 if resolved favorably.

Key Facts for Investor Verification

• Warrant Liability Impact: Verify the sensitivity of the net loss to stock price fluctuations due to the $337.5 million warrant liability classified on the balance sheet.
• Cash Runway Assumptions: Confirm the assumptions underlying the "into 2028" cash runway, specifically regarding the timing of the NDA decision and potential commercialization costs.
• Debt Covenant Compliance: Monitor the company's ability to meet the minimum cash covenant with Hercules Capital starting October 2027.
• Rescheduling Timeline: Track the DEA's rescheduling process for psilocybin, which is a critical path item for any potential revenue generation.
• UK Tax Credit Resolution: Monitor the outcome of discussions with HMRC regarding the R&D intensity condition and potential additional tax credits.